A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP

Neurobiology of Disease

Volumn 56, Issue , 2013, Pages 145-155

  Hansen, Christian ^a   Björklund, Tomas ^a   Petit, Geraldine H ^a   Lundblad, Martin ^a   Murmu, Reena Prity ^a   Brundin, Patrik ^a,b   Li, Jia Yi ^a  

^a LUND UNIVERSITY   (Sweden)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN GREEN FLUORESCENT FUSION PROTEIN; DOPAMINE; HYBRID PROTEIN; UNCLASSIFIED DRUG;

AMPEROMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BIOACCUMULATION; BRAIN REGION; CONTROLLED STUDY; DOPAMINE RELEASE; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; OLFACTORY BULB; OLFACTORY DISCRIMINATION; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ROTAROD TEST; SMELLING DISORDER; STRIATE CORTEX; SUBSTANTIA NIGRA PARS COMPACTA; TRANSGENIC MOUSE; VENTRAL TEGMENTUM; WESTERN BLOTTING; WILD TYPE;

AGING; ALPHA-SYNUCLEIN; AMPHETAMINE; ANIMALS; DISCRIMINATION (PSYCHOLOGY); DOPAMINE; DOPAMINE AGENTS; DOPAMINERGIC NEURONS; GREEN FLUORESCENT PROTEINS; HUMANS; LOCOMOTION; MICE; MICE, TRANSGENIC; MOVEMENT DISORDERS; NEOCORTEX; NERVOUS SYSTEM DISEASES; OLFACTION DISORDERS; SMELL; SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA;

EID: 84878149242     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.04.017     Document Type: Article

References (32)

1. Anwar S., et al. Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J. Neurosci. 2011, 31:7264-7274.
2. Baptista M.J., et al. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J. Neurochem. 2003, 85:957-968.
3. Brundin P., Olsson R. Can alpha-synuclein be targeted in novel therapies for Parkinson's disease?. Expert. Rev. Neurother. 2011, 11:917-919.
4. Burre J., et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
5. Chesselet M.F., et al. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics 2012, 9:297-314.
6. Chung C.Y., et al. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009, 29:3365-3373.
7. Desplats P., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13010-13015.
8. Devine M.J., et al. Parkinson's disease and alpha-synuclein expression. Mov. Disord. 2011, 26:2160-2168.
9. Fleming S.M., et al. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur. J. Neurosci. 2008, 28:247-256.
10. Freundt E.C., et al. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann. Neurol. 2012, 72:517-524.
11. Gaugler M.N., et al. Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 2012, 123:653-669.
12. Giasson B.I., et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
13. Haehner A., et al. Prevalence of smell loss in Parkinson's disease-a multicenter study. Parkinsonism Relat. Disord. 2009, 15:490-494.
14. Hansen C., Li J.Y. Beyond alpha-synuclein transfer: pathology propagation in Parkinson's disease. Trends Mol. Med. 2012, 18:248-255.
15. Hansen C., et al. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121:715-725.
16. Lee H.J., et al. Enzyme-linked immunosorbent assays for alpha-synuclein with species and multimeric state specificities. J. Neurosci. Methods 2011, 199:249-257.
17. Luk K.C., et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
18. Lundblad M., et al. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3213-3219.
19. Magen I., Chesselet M.F. Genetic mouse models of Parkinson's disease the state of the art. Prog. Brain Res. 2010, 184:53-87.
20. Matsuoka Y., et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 2001, 8:535-539.
21. Mougenot A.L., et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 2012, 33(9):2225-2228. (Sep).
22. Nath S., et al. Raised calcium promotes alpha-synuclein aggregate formation. Mol. Cell. Neurosci. 2011, 46:516-526.
23. Nemani V.M., et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
24. Petit G.H., Berkovich E., Hickery M., Kallunki P., Fog K., Fitzer-Attas C., Brundin P. Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease. PLoS One 2013, 8(4). (Epub 2013 Apr 3).
25. Rockenstein E., et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 2002, 68:568-578.
26. Rockenstein E., et al. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J. Neurosci. Res. 2005, 80:247-259.
27. Swant J., et al. Alpha-synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. J. Biol. Chem. 2011, 286:43933-43943.
28. Thiruchelvam M.J., et al. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur. J. Neurosci. 2004, 19:845-854.
29. Unni V.K., et al. In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS One 2010, 5:e10589.
30. Vekrellis K., et al. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 2011, 10:1015-1025.
31. Volpicelli-Daley L.A., et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72:57-71.
32. Waxman E.A., Giasson B.I. Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim. Biophys. Acta 2009, 1792:616-624.